Providing specialist data analytics and insights of medical imaging biomarkers in Huntington’s disease
IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed an expanded scope to a current contract, with a top 10 pharmaceutical company. Additional services will be provided, increasing the value of the contract by £0.6m to £1.6m over the three year term. This new award has occurred within the first three months of the project; the original contract was announced on 14th May 2018.
As the lead image analysis partner in this study, IXICO will apply its proprietary approaches to data science, together with in-licenced algorithms from leading academic centres, to measure neurological outcomes in study participants. The expanded scope will see IXICO providing additional analysis based on advanced imaging modalities in a natural history study of people with early manifestation of Huntington’s disease.
Giulio Cerroni, Chief Executive of IXICO, said: “I am delighted that our client has decided to expand our involvement at such an early stage of this important study. We value the strength of our relationships with pharmaceutical companies and our ability to provide them with important insights to support their efforts to bring new medicines to market.”
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, has received notification from one of its pharmaceutical clients of its decision to stop the screening, randomisation and dosing in a Phase II/III clinical study [...]
Further to the announcement on 3 May 2018 in relation to the placing of new ordinary shares in the Company to raise £5.5 million and the despatch of a related shareholder circular, IXICO plc (AIM: [...]
Commercially-led growth strategy delivers strong H1 performance Oversubscribed capital raise of £5.5m post the period end IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces its unaudited interim results for the [...]
Providing specialist imaging clinical trials services in Huntington’s disease IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announced that it has signed a new contract with a top 10 pharmaceutical company, [...]
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed amendments to current contracts which expand the clinical trial services provided to two biopharmaceutical companies. The change orders have [...]
Oversubscribed placing to raise £5.5 million at 28 pence per share, Related Party Transaction and Notice of General Meeting
Provides platform to accelerate commercial strategy to drive mid-term revenue growth IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, is pleased to announce that it is proposing to raise £5.5 million (before [...]